ASX:CU6Pharmaceuticals
Clarity Pharmaceuticals (ASX:CU6) Is Up 7.7% After Raising A$203.6 Million for Cancer Trials - What's Changed
Clarity Pharmaceuticals has completed a follow-on equity offering, raising A$203.6 million by issuing 48,485,212 ordinary shares at A$4.20 each with a A$0.21 discount per share.
This substantial capital raise highlights escalating investor interest as the company advances clinical trials of its copper-based cancer diagnostics and therapies.
We'll explore how the successful capital raising and momentum in next-generation cancer trials shapes Clarity's broader investment narrative.
Uncover the...